Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...